Anzeige
Mehr »
Login
Sonntag, 13.06.2021 Börsentäglich über 12.000 News von 662 internationalen Medien
Angehender Nickelproduzent mit 439 Mio. $ Gewinn pro Jahr!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2P9YT ISIN: ES0169501022 Ticker-Symbol: PMRA 
Tradegate
11.06.21
12:14 Uhr
77,60 Euro
+0,52
+0,67 %
Branche
Biotechnologie
Aktienmarkt
IBEX-35
1-Jahres-Chart
PHARMA MAR SA Chart 1 Jahr
5-Tage-Chart
PHARMA MAR SA 5-Tage-Chart
RealtimeGeldBriefZeit
76,7077,8219:00
76,7077,8211.06.

Aktuelle News zur PHARMAMAR Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
26.05.Spain's PharmaMar says COVID-19 treatment shows clinical efficacy in trials9
05.05.PHARMA MAR, S.A.: The Company files first quarter 2021 financial information.11
PHARMAMAR Aktie jetzt für 0€ handeln
29.04.Spain's regulator lets PharmaMar test treatment on COVID-19 patients11
29.04.PHARMA MAR, S.A.: The Company announces that it has obtained the authorization from the Spanish Agency for Medicines and Health Products (AEMPS) to initiate the Phase III NEPTUNO.5
23.04.PHARMA MAR, S.A.: The Company announces its licensing partner, Specialised Therapeutics Asia, Pte. Ltd. (STA) received marketing approval for Yondelis (trabectedin) by the Australian Therapeutic Goods Administration (TGA).4
15.04.PHARMA MAR, S.A.: The Company reports changes in the composition of its Board of Directors and of its Appointments and Compensation and Sustainability Committee.2
15.04.PHARMA MAR, S.A.: The Company informs about the dividend payment.3
15.04.PHARMA MAR, S.A.: It is reported that all proposed resolutions submitted by the Board to the General Shareholders' Meeting have been approved.2
15.04.PHARMA MAR, S.A.: Attached is a copy of the presentation to shareholders to be made at the General Shareholders' Meeting of Pharma Mar by the Chairman of the Company.1
15.04.European oncology group adds Pharma Mar's Lurbinectedin to treatment guidelines1
13.04.PHARMA MAR, S.A.: Axesor raises long-term credit rating of Pharma Mar.4
08.04.PHARMA MAR, S.A.: The Company reports details of the operations of the Liquidity Agreement between 01/01/2021 and 31/03/20215
22.03.PHARMA MAR, S.A.: The Executive Committee of Pharma Mar, S.A. has decided to implement the Free of Charge Stock Ownership Plan approved by resolution of the General Shareholders' Meeting of 18 June 2020.10
18.03.PHARMA MAR, S.A.: The Company publishes a supplementary announcement regarding the call to the Annual General Shareholders' Meeting5
10.03.PHARMA MAR, S.A.: The Company announces the call of the Ordinary General Shareholders' Meeting and submits proposed resolutions.5
01.03.PHARMA MAR, S.A.: The Company announces the signature of a new license agreement with Adium to commercialize Zepzelca (lurbinectedin) in Latin America.8
26.02.PHARMA MAR, S.A.: The Company reports draw up of the Annual Financial Statements 2020, a proposal for a dividend, resolution to convene a General Shareholders' Meeting, and a conference call with analysts and investors.4
26.02.PHARMA MAR, S.A.: The Company sends press release regarding year 2020 results together with financial report.3
17.02.Pharma Mar to trial Aplidin on hospitalised UK COVID patients21
17.02.PHARMA MAR, S.A.: The Company announces that it has obtained Medicines and Healthcare products Regulatory Agency (MHRA) approval for UK patients to participate in the Phase III NEPTUNO clinical trial.6
Seite:  Weiter >>
36 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1